Analystreport

Rubius Therapeutics Inc (NASDAQ: RUBY) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.

Rubius Therapeutics, Inc.  (RUBY) 
Last rubius therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report